Upstream Bio Statistics
Share Statistics
Upstream Bio has 53.79M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 53.79M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8,090 |
| FTD / Avg. Volume | 2.74% |
Short Selling Information
The latest short interest is 3.94M, so 7.32% of the outstanding
shares have been sold short.
| Short Interest | 3.94M |
| Short % of Shares Out | 7.32% |
| Short % of Float | 13.25% |
| Short Ratio (days to cover) | 13.28 |
Valuation Ratios
The PE ratio is -13.44 and the forward
PE ratio is -3.2.
Upstream Bio's PEG ratio is
0.13.
| PE Ratio | -13.44 |
| Forward PE | -3.2 |
| PS Ratio | 356.14 |
| Forward PS | 39 |
| PB Ratio | 1.8 |
| P/FCF Ratio | -14.14 |
| PEG Ratio | 0.13 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Upstream Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 44.63,
with a Debt / Equity ratio of 0.
| Current Ratio | 44.63 |
| Quick Ratio | 44.63 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $45,576.92 |
| Profits Per Employee | $-1,207,807.69 |
| Employee Count | 52 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0.1, so Upstream Bio's
price volatility has been higher than the market average.
| Beta | 0.1 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 8.18 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 55.19 |
| Average Volume (20 Days) | 294,985 |
Income Statement
In the last 12 months, Upstream Bio had revenue of 2.37M
and earned -62.81M
in profits. Earnings per share was 0.
| Revenue | 2.37M |
| Gross Profit | 2.37M |
| Operating Income | -77.76M |
| Net Income | -62.81M |
| EBITDA | -77.67M |
| EBIT | -77.76M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 325.89M in cash and 1.83M in
debt, giving a net cash position of 324.06M.
| Cash & Cash Equivalents | 325.89M |
| Total Debt | 1.83M |
| Net Cash | 324.06M |
| Retained Earnings | -190.78M |
| Total Assets | 456.17M |
| Working Capital | 444.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -59.17M
and capital expenditures -511K, giving a free cash flow of -59.68M.
| Operating Cash Flow | -59.17M |
| Capital Expenditures | -511K |
| Free Cash Flow | -59.68M |
| FCF Per Share | -1.16 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -3281.18% and -2650.04%.
| Gross Margin | 100% |
| Operating Margin | -3281.18% |
| Pretax Margin | -2650.04% |
| Profit Margin | -2650.04% |
| EBITDA Margin | -3277.43% |
| EBIT Margin | -3281.18% |
| FCF Margin | -2518.27% |
